In this Issue:
Genetic variation in risk-lowering benefit of NSAIDs
Adjuvant chemotherapy in stage 2 colon cancer
Test for RAS mutation before EGFR therapy
Test for YAP1 activation before EGFR therapy
Support for BRAF testing before EGFR therapy
Combined RAF/EGFR inhibition in BRAF-mutant tumours
Continuous vs intermittent chemotherapy
Consensus recommendations in patients >70 years
Delay of adjuvant chemotherapy does not impact survival
Fertility preservation counselling
Please login below to download this issue (PDF)